Repligen CORP: directors' dealings · United States · SEC (Form 4)

About Repligen CORP

Repligen Corp. (NASDAQ: RGEN) is a United States-based life sciences company listed on the NASDAQ market, focused on bioprocessing technologies used in the manufacture of biologic drugs. Headquartered in Waltham, Massachusetts, the company positions itself as a technology partner to pharmaceutical and biotechnology customers producing monoclonal antibodies, recombinant proteins, RNA-based therapeutics, vaccines, and selected cell and gene therapies. While Repligen has a long operating history in life sciences, its current profile is defined by a growth strategy centered on innovation, process efficiency, and the expansion of its proprietary product portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) Operationally, Repligen develops and commercializes a broad set of systems and consumables used across upstream and downstream biomanufacturing workflows. Its portfolio includes filtration solutions, chromatography products, process analytics, and real-time quality and process-control tools. This mix gives the company a specialized, high-value position rather than that of a broad industrial supplier. Repligen’s competitive edge comes from its focus on mission-critical process steps, its innovation cadence, and its ability to serve customers seeking higher throughput, better reproducibility, and lower manufacturing risk. In its end markets, the company competes with established life-science tools and bioprocessing suppliers, but it differentiates through technical depth and a customer-centric approach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) Repligen also has a diversified international footprint. Its corporate headquarters are in Waltham, Massachusetts, and most manufacturing sites are in the United States, complemented by key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. This geographic spread strengthens supply-chain resilience and gives the company direct access to major global bioprocessing hubs. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Launches-the-CTech-SoloVPE-PLUS-System/default.aspx?utm_source=openai)) Recent highlights reinforce the company’s strategic momentum. In early 2026, Repligen reported strong 2025 results and issued 2026 guidance pointing to further revenue growth and operating-margin expansion. During 2025, the company launched the CTech SoloVPE PLUS system, aimed at biopharmaceutical manufacturers, and acquired 908 Devices’ bioprocessing analytics portfolio, adding real-time monitoring and characterization tools. These developments support a clear investment narrative: Repligen is steadily broadening its technology platform and strengthening its position in the higher-value segment of biomanufacturing infrastructure. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai))